The ESMO Congress is a
highly influential oncology platform for clinicians, researchers, patient
advocates, journalists and healthcare industry representatives from all over
the world. https://www.esmo.org/
Several projects in which we collaborated are presented this year:
- PICTO: Benefits of using pictograms for outpatients treated for cancer and monitored by telehealth. Coralie BOITEAU, Dewi VERNEREY, Sophie PAGET-BAILLY, Joelle FRITZSCH, Julie HENRIQUES, Natividad ALARCON, Claude GANTER, Emmanuelle KEMPF, Christophe TOURNIGAND
- NIPICOL: Nivolumab plus ipilimumab in microsatellite instability high/mismatch repair-deficient metastatic colorectal cancer: final survival analysis and prognostic evaluation of GDF-15 in the GERCOR NIPICOL phase 2 study. Léonard DEPOTTE, Paula NAY, Christophe BORG, Julie HENRIQUES, Jaafar BENNOUNA, Christelle DE LA FOUCHARDIÈRE, David TOUGERON, Thibault MAZARD, Benoist CHIBAUDEL, Christophe TOURNIGAND, Dewi VERNEREY, Frédéric PIGNEUR, Thierry ANDRÉ, Romain COHEN
- Initiation of antitumor therapy in the emergency setting for life- threatening complications related to solid malignancies: is it feasible and reasonable? A. BUTHOD-GARÇON, J. HENRIQUES, A. FALCOZ, A. MEURISSE, D. VERNEREY, L. CHAIGNEAU, G. PITON, C. BORG, V. WESTEEL, F. CALCAGNO, G. CAPELLIER, A. THIERY-VUILLEMIN, E. KLAJER
- VOLATIL: Atezolizumab plus UCPvax Telomerase CD4 TH1-Inducer Cancer Vaccine for the treatment of chemorefractory HPV+ Cancers: safety and efficacy results of the VolATIL phase 2 study. Christophe BORG, Francois GHIRINGHELLI, Christelle DE LA FOUCHARDIÈRE, Benoit YOU, Elsa KALBACHER, Fernando BAZAN, Guillaume MEYNARD, Anne-Laure CLAIRET, Tristan MAURINA, Angelique VIENOT, Christine FAGNONI-LEGAT, Dewi VERNEREY, Aurelia MEURISSE, Jean David FUMET, Marie KROEMER, Magali REBUCCI-PEIXOTO, Laurie SPEHNER, Stefano KIM, Olivier ADOTEVI, Laura MANSI
-RASINTRO: Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study. Aziz ZAANAN, Elisabeth BERGEN, Ludovic EVESQUE, Aurelia MEURISSE, Pascal ARTRU, Thierry LECOMTE, Olivier BOUCHÉ, Romain CORIAT, Astrid LIÈVRE, Romain COHEN, Valérie BOIGE, Samy LOUAFI, Jean-Baptiste BACHET, Julien TAIEB, Dewi VERNEREY, Hélène BLONS, Pierre LAURENT-PUIG
- LONGBOARD: G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study. BACHET JB, BOUCHÉ O, TROUILLOUD I, GARCIA LARNICOL ML, VERNEREY D, BOISSON C, HAUTEFEUILLE V, LALY M, RINALDI Y, FENIOUX C, SMITH D, DESRAME J, LECAILLE C, CHIBAUDEL B, WAGNER JP, TEXEREAU P, VIENOT A, TOUGERON D, BORG C
- STRATEGIC: Angiopietin-2 is a candidate biomarker to guide the prescription of bevacizumab in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer— An exploratory analysis of the STRATEGIC phase III trial. Christophe BORG, Julie HENRIQUES, Dewi VERNEREY, Louis-Marie DOURTHE, Thierry ANDRE, Vincent BOURGEOIS, Pierre-Luc ETIENNE, Jérôme DESRAME, … Benoist CHIBAUDEL
A propos de Sophie PAGET-BAILLY
Sophie Paget-Bailly is a research engineer in epidemiology and clinical research. She passed with honours the East of France inter-region master’s degree in public health and occupational and environmental risks. During the master’s degree’s internship in the Interregional Epidemiology Unit of Bourgogne/Franche-Comté, she realized a quantitative health risk assessment in the context of chemical contamination of groundwater. She defended a PhD in Public Health and Epidemiology in Paris XI University, Doctoral School 420, working in the Centre for Research in Epidemiology and Population Health in Villejuif, France. During her PhD, she worked on occupational exposures and head and neck cancer, providing two systematic reviews and meta-analyses and analyzing data from the ICARE case-control study. She was also representative of the PhD students at the ED420 school council.